Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Status:
RECRUITING
Trial end date:
2027-07-30
Target enrollment:
Participant gender:
Summary
This study is a an open-label, multinational, multicenter, single-arm Phase b/ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.